BI 2536

Drug Profile

BI 2536

Alternative Names: BI 2536 BS; BI-2536

Latest Information Update: 07 Oct 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Benzamides; Piperidines; Pteridines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 07 Oct 2014 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (IV) (NCT02211833)
  • 24 Sep 2014 Discontinued - Phase-I for Solid tumours in Germany (IV-infusion)
  • 24 Sep 2014 Discontinued - Phase-II for Small cell lung cancer in USA and Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top